CYTK

Today, shares of CYTK gapped up in a big, big way. Healthcare stock Cytokinetics released news that their heart drug, Aficamten, had been successful in its most recent trial. Aficamten was shown to improve patients’ exercise capacity, increased peak oxygen capacity, and is now being considered by some analysts to be the “best in class” […]